SNTI

Senti Biosciences Holdings, Inc. (SNTI) | Rumor.io

Senti Biosciences Holdings

SNTI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,959

Bullish sentiment (50-day avg)91%

Price to earnings ratio4.27

Market capitalization9.7M

Earnings per share-1.69

Dividend yield (TTM)—

Revenue (annual)22K

Net income (annual)-61.4M

Social

What share of all stock conversation is about SNTI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0.01% +0	0% +0	0% 0

Sep 23

$SNTI is being discussed as a potential merger play, with some users expecting a significant price increase if the merger news is released.
The company has a relatively low float of 13 million shares, which could contribute to a potential price surge.
Some users are optimistic about $SNTI's potential, with one user even comparing it to a recent 100% gain in another stock ($ADGM).

Generated by AI

Sentiment

Of the messages about SNTI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	89.47% -10.53	89.67% -10.33	72.99% -10.54
Bearish	100%	10.53% +10.53	10.33% +10.33	27.01% +10.54

Bullish· Dec 12

The company has a strong FDA RMAT designation for "FAST APPROVAL", which can cut years out of the approval process and has already shown clinical efficacy.
The company has a significant amount of cash on hand, including from a private placement, and has warrants that have not yet been exercised.
The company has a strong patent portfolio, with 116 patents on gene medication, therapies, and research, and has a history of 400% price runs.

Bearish· Jul 15

The company's decision to sell its lead asset for $60 million in a garage sale deal has led to a loss of trust among investors, who are questioning the valuation of the company's new pipelines.
The recent financing deal with Celadon Partners, which includes a full-ratchet anti-dilution protection, six-month maturity with 200% cash payback, and first-priority liens on nearly all assets, has increased the dilution risk for existing shareholders.
The company's financials and funding risk have been a concern among investors, with the recent filings actually increasing the risks, and the stock reacting to financial reality rather than scientific progress.

Generated by AI

Topics

Of the messages about SNTI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	68.09%	72.73%	64.89%
Technical Analysis	0%	31.91%	27.27%	28.75%
Analysts	0%	0%	0%	5.34%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	1.02%
Macro	0%	0%	0%	0%

Announcements· Dec 9

Senti Biosciences' lead candidate SENTI-202, a CAR-NK therapy, has received FDA RMAT designation for treating relapsed or refractory acute myeloid leukemia (AML).
Early data from the ongoing Phase 2 trial showed a 50% overall response rate and 42% complete remission at the Phase 2 dose, with a median remission duration of 7.6 months.
Senti plans to move quickly toward pivotal studies and assess broader indications, including newly diagnosed AML, pediatric AML, and myelodysplastic syndrome (MDS).

Technical Analysis· Dec 9

SNTI has shown a good improvement from yesterday, with a large registered warrant, active ATM, and clear agenda.
The stock is reversing off a demand zone and is looking stable, with a possible breakout on the horizon.
SNTI's moving averages are trending upwards, and volume is increasing, with a key indicator being the 200-day moving average giving way, potentially leading to a high-volume surge and ATH break.

Generated by AI

Community

Of the messages about SNTI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	71.83%	66.99%	26.28%
Newcomers	100%	28.17%	33.01%	73.72%

Regulars· Jul 17

The post is a motivational message, not specifically about Senti Biosciences, but rather about staying focused in trading.
There is no other post in the list that is primarily about Senti Biosciences, Inc.
No market-relevant information is present in the provided post or the overall list.

Newcomers· Jun 18

The FDA has granted orphan drug designation to Senti Biosciences, Inc. for its first-in-class off-the-shelf logic-gated selective CD33 OR FLT3 NOT EMCN CAR NK cell therapy, SENTI-202, to treat Acute Myeloid Leukemia.
Newcomers are taking a bullish stance on SNTI, with some expecting it to reach $3.74+ and others predicting it will go "way up" due to its potential to shift the treatment paradigm for AML.
The company's float is under 8M, and its stock has seen heavy volume following the FDA's designation, with some traders expecting it to trap and run if it reclaims $2.95.

Generated by AI

Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million. Conexeu Sciences (NASDAQ:CNXU)

2mo agoBenzinga

Senti Biosciences to spin off gene therapy unit for CVR

2mo agoInvesting.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

Senti Biosciences Holdings, Inc. to Advance Controllable Cell and Gene Therapies Leveraging the Regulator Dial Platform™Spin-off of Senti Biosciences, Inc., including SENTI-202, Aims to Unlock Value via Contingent Value Right to Potential Future Milestone Payments of up to $60 Million for Logic-Gated SENTI-202 Development and Commercialization SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) (“SBH” or the “Company”) today announced a

2mo agoYahoo Finance

Also Discussed

Investors talking about SNTI also mention

#	Name	Attention
1	PaxMedica Inc.PXMD	0%0
2	Cardio Diagnostics Holdings, Inc.CDIO	0%0
3	MGRM - Monogram Orthopaedics, Inc.	——
4	GRTS - Gritstone bio, Inc.	——
5	CYTO - Altamira Therapeutics Ltd.	——
6	CareCloud Inc.CCLD	0%new
7	Avenue Therapeutics Inc.ATXI	0%new
8	noco-noco Inc.NCNC	0%0
9	LMDX - LumiraDx Limited	——
10	PEGY - Pineapple Energy Inc.	——

Senti Biosciences Holdings, Inc.

Healthcare
Biotechnology

Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies built with its proprietary Gene Circuit platform. The company designs engineered medicines that can sense biological signals, make programmed decisions, and respond with greater precision in complex disease environments. Its current work centers on advanced cell therapies for difficult-to-treat cancers and other incurable diseases, with applications across both liquid and solid tumors. Senti Biosciences Holdings, Inc. develops these programs using synthetic biology tools intended to improve targeting, control, and selectivity in therapeutic cells. Headquartered in South San Francisco, California, the company operates in the biotechnology and cell therapy markets, where it contributes to the broader effort to create more precise and controllable genetic medicines.

Website

Location

2 Corporate Drive

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about SNTI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0.01% +0	0% +0	0% 0

Sep 23

$SNTI is being discussed as a potential merger play, with some users expecting a significant price increase if the merger news is released.
The company has a relatively low float of 13 million shares, which could contribute to a potential price surge.
Some users are optimistic about $SNTI's potential, with one user even comparing it to a recent 100% gain in another stock ($ADGM).

Generated by AI

Sentiment

Of the messages about SNTI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	89.47% -10.53	89.67% -10.33	72.99% -10.54
Bearish	100%	10.53% +10.53	10.33% +10.33	27.01% +10.54

Bullish· Dec 12

The company has a strong FDA RMAT designation for "FAST APPROVAL", which can cut years out of the approval process and has already shown clinical efficacy.
The company has a significant amount of cash on hand, including from a private placement, and has warrants that have not yet been exercised.
The company has a strong patent portfolio, with 116 patents on gene medication, therapies, and research, and has a history of 400% price runs.

Bearish· Jul 15

The company's decision to sell its lead asset for $60 million in a garage sale deal has led to a loss of trust among investors, who are questioning the valuation of the company's new pipelines.
The recent financing deal with Celadon Partners, which includes a full-ratchet anti-dilution protection, six-month maturity with 200% cash payback, and first-priority liens on nearly all assets, has increased the dilution risk for existing shareholders.
The company's financials and funding risk have been a concern among investors, with the recent filings actually increasing the risks, and the stock reacting to financial reality rather than scientific progress.

Generated by AI

Topics

Of the messages about SNTI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	68.09%	72.73%	64.89%
Technical Analysis	0%	31.91%	27.27%	28.75%
Analysts	0%	0%	0%	5.34%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	1.02%
Macro	0%	0%	0%	0%

Announcements· Dec 9

Senti Biosciences' lead candidate SENTI-202, a CAR-NK therapy, has received FDA RMAT designation for treating relapsed or refractory acute myeloid leukemia (AML).
Early data from the ongoing Phase 2 trial showed a 50% overall response rate and 42% complete remission at the Phase 2 dose, with a median remission duration of 7.6 months.
Senti plans to move quickly toward pivotal studies and assess broader indications, including newly diagnosed AML, pediatric AML, and myelodysplastic syndrome (MDS).

Technical Analysis· Dec 9

SNTI has shown a good improvement from yesterday, with a large registered warrant, active ATM, and clear agenda.
The stock is reversing off a demand zone and is looking stable, with a possible breakout on the horizon.
SNTI's moving averages are trending upwards, and volume is increasing, with a key indicator being the 200-day moving average giving way, potentially leading to a high-volume surge and ATH break.

Generated by AI

Community

Of the messages about SNTI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	71.83%	66.99%	26.28%
Newcomers	100%	28.17%	33.01%	73.72%

Regulars· Jul 17

The post is a motivational message, not specifically about Senti Biosciences, but rather about staying focused in trading.
There is no other post in the list that is primarily about Senti Biosciences, Inc.
No market-relevant information is present in the provided post or the overall list.

Newcomers· Jun 18

The FDA has granted orphan drug designation to Senti Biosciences, Inc. for its first-in-class off-the-shelf logic-gated selective CD33 OR FLT3 NOT EMCN CAR NK cell therapy, SENTI-202, to treat Acute Myeloid Leukemia.
Newcomers are taking a bullish stance on SNTI, with some expecting it to reach $3.74+ and others predicting it will go "way up" due to its potential to shift the treatment paradigm for AML.
The company's float is under 8M, and its stock has seen heavy volume following the FDA's designation, with some traders expecting it to trap and run if it reclaims $2.95.

Generated by AI

Senti Biosciences Holdings

Social

Sep 23

Sentiment

Bullish· Dec 12

Bearish· Jul 15

Topics

Announcements· Dec 9

Technical Analysis· Dec 9

Community

Regulars· Jul 17

Newcomers· Jun 18

News

12 Health Care Stocks Moving In Wednesday's Intraday Session - China Pharma Holding (AMEX:CPHI), Conexeu

Senti Biosciences to spin off gene therapy unit for CVR

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

Also Discussed

Senti Biosciences Holdings, Inc.

Company Information

Location

News

12 Health Care Stocks Moving In Wednesday's Intraday Session - China Pharma Holding (AMEX:CPHI), Conexeu

Senti Biosciences to spin off gene therapy unit for CVR

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

Also Discussed

Social

Sep 23

Sentiment

Bullish· Dec 12

Bearish· Jul 15

Topics

Announcements· Dec 9

Technical Analysis· Dec 9

Community

Regulars· Jul 17

Newcomers· Jun 18